Peptide-Nucleic Acids TRIZ Cases

See how dual-domain peptides bind to textiles and scavenge chlorine in wash and rinse cycles to

Novel intermediates, nanofiltration, and selective deprotection raise tirzepatide purity and yield while reducing waste and harsh conditions.

Conserved LOS-mimicking peptides trigger bactericidal antibodies against N. gonorrhoeae and help overcome antigenic variability.

A single chimeric protein activates GLP-1, GIP, and glucagon receptors to lower blood glucose and body weight with less treatment complexity.

Nanofiltration, selective lysine acylation, and radical desulfurization improve tirzepatide purity and yield while reducing waste and harsh reagents.

Engineered peptides block OPN signaling in microglia and macrophages to curb glioma invasiveness and improve immunotherapy response.

Segmented solid-phase synthesis forms a cyclic peptide core before chain extension to improve purity, yield, and final purification.

Covalently linking mucin-binding and virus-binding peptides helps trap respiratory viruses in mucus and reduce infection risk.

Sequence-modified GLP-1 peptides improve glucose, lipid, and weight control while reducing dose-related gastrointestinal side effects.

Continuous flow native chemical ligation enables rapid, scalable polypeptide synthesis and UV-driven desulfurization or deselenization.

Tumor-targeting liposomes and nanodiamond carriers improve anti-cancer drug accumulation in tumors to reduce primary and metastatic growth.

Macrocyclic peptide ligands and linked epitopes improve CD8 binding stability, enabling more sensitive and selective CD8+ T-cell detection.

Fatty acid chain conjugation extends GLP-1/GIP dual agonist half-life while reducing GI reactions and enabling once-weekly dosing.

Unnatural amino acids and a fatty acid chain help this GLP-1 agonist resist DPP IV, extend dosing, and improve glucose and weight control.

Covalently linked polyproline peptide scaffolds replace toxic metal or aromatic cages with a stable, biocompatible host structure.

Dual-stapled GLP-1R/GIPR peptide agonists improve glucose and lipid metabolism with weight-loss benefit and lower hypoglycemia risk.

Novel small molecule GIP/GLP-1 dual agonists treat fatty liver disorders while reducing dose-limiting nausea and diarrhea.

Phosphate buffer with mannitol or sodium chloride keeps dual GLP-1/GLP-2 injections isotonic while limiting peptide degradation.

Rigid EAAAK linkers stabilize lipopeptide α-helices, sharply boosting broad-spectrum coronavirus fusion inhibition.

Electrophilic stapled peptides covalently bind target cysteine residues to improve affinity, selectivity, and resistance to drug escape.

Amino acid substitutions in Ig binding proteins preserve antibody binding during alkaline cleaning, enabling reusable affinity matrices.

Synthetic self-assembling peptides form hapten carriers with T-cell epitopes, cutting vaccine development time, cost, and manufacturing complexity.

Oligopeptides improve aqueous solubility for intravitreal injection while preserving FasL inhibition and photoreceptor protection.

Linking multiple ubenimex molecules to a lysine-containing polypeptide raises effective solid cancer activity without impractical high-dose dosing.

Sequence-specific polypeptide changes improve GLP-1R/GIPR agonism, plasma stability, and pharmacokinetics for NASH-related metabolic treatment.

Topical glutamine-rich peptides restore the skin barrier and help clear inflammatory cells without broad immunosuppression.

Targeted amino acid substitutions in SH2 domains strengthen pTyr binding through hydrophobic interactions and hydrogen bonding.

Smaller B7-H3-binding conjugates improve tumor penetration and targeted radionuclide delivery while limiting damage to healthy tissue.

Iodinated polyamide crosslinkers raise hydrogel radiopacity while preserving crosslink density for clearer medical imaging.

Oligopeptide Fas inhibitors improve aqueous solubility and stability, enabling intravitreal retinal protection against photoreceptor death.

Adding a mutated variant protein to culture medium boosts cell or microorganism growth and helps maintain vitality under adverse conditions.

Well-defined peptide dendrimers use hydrophobic cores and pH-triggered shape changes to deliver nucleic acids with efficient, reproducible transfection.

Bicyclic peptide ligands linked to detectable moieties improve selective binding to transmembrane cancer targets for rapid tumor imaging and treatment.

Selective ENAH EVH1-binding peptides overcome overlapping Ena/VASP specificity to curb metastasis and reduce taxane resistance.

A balanced GLP-1/GIP dual agonist extends half-life while improving blood glucose and weight control with lower hypoglycemia risk.

Specific amino acid changes create a polypeptide that selectively inhibits Nav1.7 channels to reduce neuronal excitability and pain.

Intramolecular Diels-Alder cycloadditions stabilize peptide folds in aqueous conditions while preserving compatibility with diverse sequences.

A lipolytic peptide composition reduces intracellular lipid droplets and cellulite while avoiding the side effects of conventional obesity drugs.

A peptide extended to interact with RBD residues D420 and K458 increases binding affinity and may better block SARS-CoV-2 entry.

Covalently click-linked peptide bundles preserve protein-like structural specificity while enabling customizable fibers and liquid crystal materials.

Chemoselective methionine conversion avoids racemization and moderate yields while enabling functional homocysteine residues and tunable polypeptide solubility.

A tricyclic polypeptide-drug conjugate improves Nectin-4 binding and tumor inhibition while extending treatment potential across solid tumors.

Tetrameric coiled-coil peptide bundlemers place crosslinking groups precisely to form more homogeneous networks with tunable mechanical properties.

AI-guided microbial vesicles anchor non-bacterial proteins to deliver mRNA with lower liver accumulation, reduced immune activation, and scalable targeting.

Synthetic polypeptide nanocages encapsulate oligonucleotides to improve cell entry, protect cargo from nucleases, and enable controlled release.

Non-covalent slider peptides on peptide amphiphile nanofibers improve localization, stability, and CSPG inhibition for chronic spinal cord injury.